MedTrace Logo

Safety of SNK01 in Subjects With Alzheimer's Disease (ASK-AD)

NCT04678453 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2024-03-01

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of SNK01 (autologous natural killer cell), as a single agent, for the treatment of subjects with Alzheimer's disease.

Conditions

Interventions

BIOLOGICAL

SNK01

Patient-specific ex vivo expanded autologous natural killer cells

Sponsors & Collaborators

  • NKGen Biotech, Inc.

    lead INDUSTRY

Principal Investigators

  • Clemente Humberto Zúñiga Gil, MD · Hospital Angeles Tijuana

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
55 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-06
Primary Completion
2023-08-16
Completion
2024-01-31
FDA Drug
Yes

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04678453 on ClinicalTrials.gov